Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01443468 · ClinicalTrials.gov registry record

Clinical and Genetic Studies of Li-Fraumeni Syndrome

A clinical trial of Neoplasms and Li-Fraumeni Syndrome, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
5,000
Enrollment target
2
Study locations

NCT01443468 is a study of Neoplasms and Li-Fraumeni Syndrome that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 5,000 participants, above the 1,590-participant average among 158 other Neoplasms trials with a reported enrollment target (214% higher). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01443468, a study of Neoplasms and Li-Fraumeni Syndrome, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
5,000 participants
Enrollment target
2
Study locations

Study Summary

Background: \- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS is a change (called a mutation ) in a gene known as TP53. However, not all people with LFS have a TP53 mutation. Researchers want to study other possible genetic causes of LFS, and factors that may increase or decrease cancer risk in people with the syndrome. Objectives: * To learn more about the types of cancers that occur in individuals with LFS. * To study the role of the TP53 gene in the development of cancer. * To look for other possible genes that cause LFS * To study the effect of LFS diagnosis on families. * To determine if environmental factors or other genes can change a person s cancer risk associated with LFS. Eligibility: * Individuals with a family or personal medical history of cancers consistent with LFS. * Individuals with a family or personal medical history of cancers that does not meet the diagnosis of LFS, but the history is suggestive for LFS (meets the diagnosis for the so-called Li-Fraumeni like syndrome) * Individuals with certain rare cancers * Individuals with a family or personal history of a TP53 gene mutation, with or without related cancer(s). Design: * Participants will fill out a medical history questionnaire and a family history questionnaire. * Blood samples will be collected for DNA and for storage. Cheek cell samples may be collected if blood cannot be obtained for DNA. Participants can choose to have or not have cancer screening with blood tests, imaging studies, and other exams. * Participants will complete questionnaires about their worries about cancer, stress levels, and coping strategies. Diet and physical activity questionnaires will also be given. Other psychological tests may be given as needed. * Participants will be mon

Study Locations (2)

Maryland

  • National Cancer Institute - Shady Grove - Bethesda
  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2012-01-17

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT01443468

The ClinicalTrials.gov registry entry for NCT01443468 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,590-participant average among 158 other Neoplasms trials with a reported enrollment target (214% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.

NCT01443468 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT01443468 about?

NCT01443468 is a clinical study titled "Clinical and Genetic Studies of Li-Fraumeni Syndrome". Background: \- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS i...

What is the current status of trial NCT01443468?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2012-01-17.

What conditions does trial NCT01443468 study?

This clinical trial studies the following conditions: Neoplasms, Li-Fraumeni Syndrome, Tp53 Mutations.

Who is sponsoring clinical trial NCT01443468?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01443468 being conducted?

This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.